CybeRelease: (OTC: AMZB) Moving Forward With Its Phase I/II Clinical Trial Preparations
(CybeRelease, February 26, 2007) - Amazon Biotech, Inc. (OTC BB: AMZB) (Frankfurt: B2D.F) has been issued a patent from the United States Patent and Trademark Office, patent # 7,160,561 for “a herbal composition and method of treating HIV infection.”
AMZ0026, a therapeutic herbal composition, is Amazon Biotech’s primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Harbinger Research LLC, an independent research firm, issued a Research Brief. The report provides a description of Amazon Biotech’s business, industry, product, strategy, management team, and investment opportunities and risks. The report also includes a rating and price target.
The report is available free of charge at http://www.harbingerresearch.com/viewCompany.php?company=21.
About Harbinger Research, LLC:
Harbinger Research is a quality-leading New York-based independent equity research company that provides insightful, in-depth equity research coverage and informational reports to smaller U.S. traded companies and the individuals and institutions that invest in them.
For further information on Harbinger Research, please visit www.harbingerresearch.com
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company’s first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market.
Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com.
For more information, go to http://biz.yahoo.com/iw/070226/0219789.html
For a Free Newsletter, go to http://www.OTCReporter.com
CybeRelease Gainers are STATS ChipPAC Ltd. (Nasdaq: STTS), Itron, Inc. (Nasdaq: ITRI), JAKKS Pacific, Inc. (Nasdaq: JAKK), Conolog Corporation (Nasdaq: CNLG), EMCORE Corporation (Nasdaq: EMKR), DayStar Technologies, Inc. (Nasdaq: DSTI), Internet Gold Golden Lines Ltd. (Nasdaq: IGLD) and GulfMark Offshore, Inc. (Nasdaq: GMRK).
CybeRelease Decliners are Arris Group Inc (Nasdaq: ARRS), JetBlue Airways Corporation (Nasdaq: JBLU), Conceptus, Inc. (Nasdaq: CPTS), SiRF Technology Holdings, Inc. (Nasdaq: SIRF), Hyperion Solutions Corporation (Nasdaq: HYSL), Alaska Communications Systems Group, Inc. (Nasdaq: ALSK), U.S. Concrete, Inc. (Nasdaq: RMIX) and UAL Corporation (Nasdaq: UAUA).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation, do no trading of any kind and send No Faxes or Emails.
- Contact Information
- C. P. Barry
- Media Contact
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.